Login Register Cart 0
Generic placeholder image

Current Radiopharmaceuticals

Editor-in-Chief

ISSN (Print): 1874-4710
ISSN (Online): 1874-4729

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Application of 68Ga-PSMA-11 PET/CT in the Diagnosis of Prostate Cancer Clinical Relapse

Author(s): Regina Paula Soares Diego*, Gandhi Rádis-Baptista*, Ricardo Vale Albino Oliveira Filho, Estelita Tinoco Branco de Albuquerque, José Daniel Vieira de Castro, Katyane Moreira dos Santos, Joelan Ângelo de Lucena Santos, Guilherme Freire da Silveira Oliveira and Poliane Ângelo de Lucena Santos

Volume 15, Issue 3, 2022

Published on: 01 April, 2022

Page: [228 - 235] Pages: 8

DOI: 10.2174/1874471015666220223100750

Price: $65

Abstract

Background: This work aims to present a nuclear medicine imaging service’s data regarding applying positron emission–computing tomography (PET/CT) scans with the radiopharmaceutical 68Ga-PSMA-HBED-CC (68Ga-PSMA-11) to diagnose prostate cancer clinical relapse.

Methods: Eighty patients with a mean age of 68.26 years and an average prostatic-specific antigen blood level of 7.49 ng/ml (lower concentration = 0.17 ng/ml) received 68Ga-PSMA-11 intravenously, and full-body images of PET-CT scan were obtained. Of the total of patients admitted to the imaging service, 87.5% were examined for disease’s biochemical recurrence and clinical relapse, and 70.0% had a previous radical prostatectomy (RP).

Results: Of the patients without RP, 95.8% were detected with intra-glandular disease. The 68Ga- PSMA-11 PET/CT imaging results revealed small lesions, even in patients with low blood levels of prostatic-specific antigen, mainly in metastatic cancer cases in lymph nodes and bones.

Conclusion: The 68Ga-PSMA-11 PET/CT imaging was essential in detecting prostate cancer, with significantly high sensitivity in detecting recurrent cases. Due to its inherent reliability and sensitivity, PET/CT scanning with 68Ga-PSMA-11 received an increasing number of medical requests throughout the present follow-up study, confirming the augmented demand for this clinical imaging procedure in the regional medical community.

Keywords: 68GA-PSMA-11 PET/CT, radiopharmaceutical, peptide ligand, cancer biomarker, prostate cancer, biochemical recurrence, 68Ga-radiotracer.

« Previous Next »
Graphical Abstract

[1]
Health BMo. Prostate Cancer, (Câncer de próstata) 2019
[2]
Hövels, A.M.; Heesakkers, R.A.; Adang, E.M.; Jager, G.J.; Strum, S.; Hoogeveen, Y.L.; Severens, J.L.; Barentsz, J.O. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin. Radiol., 2008, 63(4), 387-395.
[http://dx.doi.org/10.1016/j.crad.2007.05.022] [PMID: 18325358]
[3]
Jadvar, H. Molecular imaging of prostate cancer: PET radiotracers. AJR Am. J. Roentgenol., 2012, 199(2), 278-291.
[http://dx.doi.org/10.2214/AJR.12.8816] [PMID: 22826388]
[4]
Anand, S.S.; Singh, H.; Dash, A.K. Clinical applications of PET and PET-CT. Med. J. Armed Forces India, 2009, 65(4), 353-358.
[http://dx.doi.org/10.1016/S0377-1237(09)80099-3] [PMID: 27408291]
[5]
Bouchelouche, K.; Turkbey, B.; Choyke, P.L. PSMA PET and radionuclide therapy in prostate cancer. Semin. Nucl. Med., 2016, 46(6), 522-535.
[http://dx.doi.org/10.1053/j.semnuclmed.2016.07.006] [PMID: 27825432]
[6]
Farolfi, A.; Ceci, F.; Castellucci, P.; Graziani, T.; Siepe, G.; Lambertini, A.; Schiavina, R.; Lodi, F.; Morganti, A.G.; Fanti, S. 68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy. Eur. J. Nucl. Med. Mol. Imaging, 2019, 46(1), 11-19.
[http://dx.doi.org/10.1007/s00259-018-4066-4] [PMID: 29905907]
[7]
Barbosa, F.D.; Queiroz, M.A.; Nunes, R.F.; Marin, J.F.; Buchpiguel, C.A.; Cerri, G.G. Clinical perspectives of PSMA PET/MRI for pros-tate cancer. Clinics (São Paulo), 2018, 73.
[8]
Fendler, W.P.; Eiber, M.; Beheshti, M.; Bomanji, J.; Ceci, F.; Cho, S.; Giesel, F.; Haberkorn, U.; Hope, T.A.; Kopka, K.; Krause, B.J.; Mottaghy, F.M.; Schöder, H.; Sunderland, J.; Wan, S.; Wester, H.J.; Fanti, S.; Herrmann, K. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur. J. Nucl. Med. Mol. Imaging, 2017, 44(6), 1014-1024.
[http://dx.doi.org/10.1007/s00259-017-3670-z] [PMID: 28283702]
[9]
Costello, F.; Langhorst, S.; Metter, D.; Palestro, C.; Zanzonico, P. ACMUI sub-committee report on Ge-68/Ga-68 generator licensing guidance, Final Report. 2016, 1-18..
[10]
Afshar-Oromieh, A.; Hetzheim, H.; Kratochwil, C.; Benesova, M.; Eder, M.; Neels, O.C.; Eisenhut, M.; Kübler, W.; Holland-Letz, T.; Giesel, F.L.; Mier, W.; Kopka, K.; Haberkorn, U. The theranostic PSMA Ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: Biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J. Nucl. Med., 2015, 56(11), 1697-1705.
[http://dx.doi.org/10.2967/jnumed.115.161299] [PMID: 26294298]
[11]
Queiroz, M.A.; Viana, P.; Santos, A.; Bastos, D.; Etchebehere, E.; Cerri, G. Clinical impact of 68Ga-PSMA PET/CT in a patient with biochemical recurrence of prostate cancer. Clin. Nucl. Med., 2016, 41(9), e417-e419.
[http://dx.doi.org/10.1097/RLU.0000000000001264] [PMID: 27276202]
[12]
Kletting, P.; Schuchardt, C.; Kulkarni, H.R.; Shahinfar, M.; Singh, A.; Glatting, G.; Baum, R.P.; Beer, A.J. Investigating the effect of lig-and amount and injected therapeutic activity: A simulation study for 177Lu-labeled PSMA-targeting peptides. PLoS One, 2016, 11(9), e0162303.
[http://dx.doi.org/10.1371/journal.pone.0162303] [PMID: 27611841]
[13]
Kallur, K.G.; Ramachandra, P.G.; Rajkumar, K.; Swamy, S.S.; Desai, I.; Rao, R.M.; Patil, S.G.; Sridhar, P.S.; Madhusudhan, N.; Krish-nappa, R.S.; Bhadrasetty, V.; Kumara, H.M.; Santhosh, S.D.; Ajaikumar, B.S. Clinical utility of Gallium-68 PSMA PET/CT scan for prostate cancer. Indian J. Nucl. Med., 2017, 32(2), 110-117.
[http://dx.doi.org/10.4103/0972-3919.202255] [PMID: 28533638]
[14]
Lenzo, N.P.; Meyrick, D.; Turner, J.H. Review of Gallium-68 PSMA PET/CT imaging in the management of prostate cancer. Diagnostics (Basel), 2018, 8(1), 8.
[http://dx.doi.org/10.3390/diagnostics8010016] [PMID: 29439481]
[15]
Machulkin, A.E.; Ivanenkov, Y.A.; Aladinskaya, A.V.; Veselov, M.S.; Aladinskiy, V.A.; Beloglazkina, E.K.; Koteliansky, V.E.; Shakhbazyan, A.G.; Sandulenko, Y.B.; Majouga, A.G. Small-molecule PSMA ligands. Current state, SAR and perspectives. J. Drug Target., 2016, 24(8), 679-693.
[http://dx.doi.org/10.3109/1061186X.2016.1154564] [PMID: 26887438]
[16]
Hamed, M.A.G.; Basha, M.A.A.; Ahmed, H.; Obaya, A.A.; Afifi, A.H.M.; Abdelbary, E.H. 68Ga-PSMA PET/CT in patients with rising prostatic-specific antigen after definitive treatment of prostate cancer: Detection efficacy and diagnostic accuracy. Acad. Radiol., 2019, 26(4), 450-460.
[http://dx.doi.org/10.1016/j.acra.2018.05.020] [PMID: 29935970]
[17]
Ahmadzadehfar, H.; Rahbar, K.; Kürpig, S.; Bögemann, M.; Claesener, M.; Eppard, E.; Gärtner, F.; Rogenhofer, S.; Schäfers, M.; Essler, M. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res., 2015, 5(1), 114.
[http://dx.doi.org/10.1186/s13550-015-0114-2] [PMID: 26099227]
[18]
Rahbar, K.; Schmidt, M.; Heinzel, A.; Eppard, E.; Bode, A.; Yordanova, A.; Claesener, M.; Ahmadzadehfar, H. Response and tolerabil-ity of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: A multicenter retrospective analysis. J. Nucl. Med., 2016, 57(9), 1334-1338.
[http://dx.doi.org/10.2967/jnumed.116.173757] [PMID: 27056618]
[19]
Pyka, T.; Okamoto, S.; Dahlbender, M.; Tauber, R.; Retz, M.; Heck, M.; Tamaki, N.; Schwaiger, M.; Maurer, T.; Eiber, M. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 2016, 43(12), 2114-2121.
[http://dx.doi.org/10.1007/s00259-016-3435-0] [PMID: 27290607]
[20]
Afshar-Oromieh, A.; Avtzi, E.; Giesel, F.L.; Holland-Letz, T.; Linhart, H.G.; Eder, M.; Eisenhut, M.; Boxler, S.; Hadaschik, B.A.; Kratochwil, C.; Weichert, W.; Kopka, K.; Debus, J.; Haberkorn, U. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 2015, 42(2), 197-209.
[http://dx.doi.org/10.1007/s00259-014-2949-6] [PMID: 25411132]
[21]
Eiber, M.; Maurer, T.; Souvatzoglou, M.; Beer, A.J.; Ruffani, A.; Haller, B.; Graner, F.P.; Kübler, H.; Haberkorn, U.; Eisenhut, M.; Wester, H.J.; Gschwend, J.E.; Schwaiger, M. Evaluation of Hybrid ⁶⁸Ga-PSMA ligand PET/CT in 248 patients with biochemical recur-rence after radical prostatectomy. J. Nucl. Med., 2015, 56(5), 668-674.
[http://dx.doi.org/10.2967/jnumed.115.154153] [PMID: 25791990]
[22]
Verburg, F.A.; Pfister, D.; Heidenreich, A.; Vogg, A.; Drude, N.I.; Vöö, S.; Mottaghy, F.M.; Behrendt, F.F. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur. J. Nucl. Med. Mol. Imaging, 2016, 43(3), 397-403.
[http://dx.doi.org/10.1007/s00259-015-3240-1] [PMID: 26563121]
[23]
Morigi, J.J.; Stricker, P.D.; van Leeuwen, P.J.; Tang, R.; Ho, B.; Nguyen, Q.; Hruby, G.; Fogarty, G.; Jagavkar, R.; Kneebone, A.; Hickey, A.; Fanti, S.; Tarlinton, L.; Emmett, L. Prospective comparison of &lt;sup&gt;18&lt;/sup&gt;F-fluoromethylcholine versus &lt;sup&gt;68&lt;/sup&gt;Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being con-sidered for targeted therapy. J. Nucl. Med., 2015, 56, 1185.
[http://dx.doi.org/10.2967/jnumed.115.160382] [PMID: 26112024]
[24]
Mattiolli, A.B.; Santos, A.; Vicente, A.; Queiroz, M.; Bastos, D.; Herchenhorn, D.; Srougi, M.; Peixoto, F.A.; Morikawa, L.; da Silva, J.L.F.; Etchebehere, E. Impact of 68GA-PSMA PET/CT on treatment of patients with recurrent/metastatic high risk prostate cancer - a multicenter study. Int. Braz J Urol, 2018, 44(5), 892-899.
[http://dx.doi.org/10.1590/s1677-5538.ibju.2017.0632] [PMID: 30088720]
[25]
Prado Júnior, L.M.; Marino, F.M.; Barra, R.; do Prado, L.F.M.; Barra Sobrinho, A. One-year experience with 68Ga-PSMA PET/CT: ap-plications and results in biochemical recurrence of prostate cancer. Radiol. Bras., 2018, 51(3), 151-155.
[http://dx.doi.org/10.1590/0100-3984.2017.0008] [PMID: 29991835]
[26]
Virgolini, I.; Decristoforo, C.; Haug, A.; Fanti, S.; Uprimny, C. Current status of theranostics in prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 2018, 45(3), 471-495.
[http://dx.doi.org/10.1007/s00259-017-3882-2] [PMID: 29282518]
[27]
Lawhn-Heath, C.; Salavati, A.; Behr, S.C.; Rowe, S.P.; Calais, J.; Fendler, W.P.; Eiber, M.; Emmett, L.; Hofman, M.S.; Hope, T.A. Pros-tate-specific membrane antigen PET in prostate cancer. Radiology, 2021, 299(2), 248-260.
[http://dx.doi.org/10.1148/radiol.2021202771] [PMID: 33787338]
[28]
Hofman, M.S.; Hicks, R.J.; Maurer, T.; Eiber, M. Prostate-specific Membrane Antigen PET: Clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics, 2018, 38(1), 200-217.
[http://dx.doi.org/10.1148/rg.2018170108] [PMID: 29320333]
[29]
Hofman, M.S.; Lawrentschuk, N.; Francis, R.J.; Tang, C.; Vela, I.; Thomas, P.; Rutherford, N.; Martin, J.M.; Frydenberg, M.; Shakher, R.; Wong, L.M.; Taubman, K.; Ting , Lee S.; Hsiao, E.; Roach, P.; Nottage, M.; Kirkwood, I.; Hayne, D.; Link, E.; Marusic, P.; Matera, A.; Herschtal, A.; Iravani, A.; Hicks, R.J.; Williams, S.; Murphy, D.G. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet, 2020, 395(10231), 1208-1216.
[http://dx.doi.org/10.1016/S0140-6736(20)30314-7] [PMID: 32209449]
[30]
Chudasama, Y.V.; Gillies, C.L.; Zaccardi, F.; Coles, B.; Davies, M.J.; Seidu, S.; Khunti, K. Impact of COVID-19 on routine care for chronic diseases: A global survey of views from healthcare professionals. Diabetes Metab. Syndr., 2020, 14(5), 965-967.
[http://dx.doi.org/10.1016/j.dsx.2020.06.042] [PMID: 32604016]

Rights & Permissions Print Cite
Article Metrics
32
1
© 2024 Bentham Science Publishers | Privacy Policy